Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RODEO patient-guided TKI dose reduction in chronic myeloid leukemia
NL-OMON52067Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imatinib, bosutinib, dasatinib, nilotinib and ponatinib in chronic myelogenous leukemia (CML), sponsored by Radboud University Medical Center. Primary endpoint: Intervention failure at 12 months after first dose reduction. Started Jun 2022; status: recruiting.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON52067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52067.